Allen Kaplan to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Allen Kaplan has written about Antibodies, Monoclonal, Humanized.
Connection Strength
1.827
-
Biologic agents and the therapy of chronic spontaneous urticaria. Curr Opin Allergy Clin Immunol. 2014 Aug; 14(4):347-53.
Score: 0.425
-
Therapy of chronic urticaria: a simple, modern approach. Ann Allergy Asthma Immunol. 2014 May; 112(5):419-25.
Score: 0.415
-
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013 Jul; 132(1):101-9.
Score: 0.394
-
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017 Apr; 72(4):519-533.
Score: 0.126
-
The maddening itch: an approach to chronic urticaria. J Investig Allergol Clin Immunol. 2014; 24(1):1-5.
Score: 0.102
-
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar 07; 368(10):924-35.
Score: 0.096
-
Biologic agents in the treatment of urticaria. Curr Allergy Asthma Rep. 2012 Aug; 12(4):288-91.
Score: 0.093
-
Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol. 2011 May; 127(5):1300-2.
Score: 0.084
-
Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008 Sep; 122(3):569-73.
Score: 0.071
-
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011 Sep; 128(3):567-73.e1.
Score: 0.022